Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Tribe Clinical Research LLC

Neither a doctor nor a teaching hospital

Research payments

$15,269,491

1,523 payments

Through program year 2025, Tribe Clinical Research LLC is reported as receiving $15,269,491 in research payments, across 1,523 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $3,712,451 376
2024 Research $3,283,018 154
2023 Research $2,855,601 322
2022 Research $3,105,213 371
2021 Research $1,641,981 271
2020 Research $671,227 29

Breakdown

Who paid Research payments · program years 2020–2025
  1. Eli Lilly and Company $9,642,590 159 payments
  2. GlaxoSmithKline, LLC. $1,812,479 366 payments
  3. Pfizer Inc. $1,417,692 118 payments
  4. Merck Sharp & Dohme Corporation $426,818 4 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $389,148 36 payments
  6. Sanofi Pasteur Inc. $368,409 24 payments
  7. AbbVie, Inc. $368,210 121 payments
  8. Novavax Inc $291,468 57 payments
  9. Regeneron Pharmaceuticals, Inc. $253,081 101 payments
  10. Esperion Therapeutics, Inc. $73,565 130 payments
Studies the money was for Research payments · program years 2020–2025
  1. A Master Protocol to Investigate the Efficacy and Safety of Ly3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity Or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (Triumph-1) $1,272,175 8 payments
  2. A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $850,385 46 payments
  3. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(A) Who Have Established Atherosclerotic Cardiovascular Disease Or Are at Risk for A First Cardiovascular Event - Acclaim-Lp(A) $801,540 3 payments
  4. A Phase 3B Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Compared to Semaglutide 2.4 MG in Adults Who Have Obesity Or Overweight With Weight-Related Comorbidities (Surmount-5) $628,436 2 payments
  5. A Phase 3B, Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Compared to Semaglutide 2.4 MG in Adults Who Have Obesity Or Overweight With Weight-Related Comorbidities (Surmount-5) $607,108 5 payments
  6. Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity Or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (Surmount-1) $589,451 7 payments
  7. A Master Protocol to Investigate the Efficacy and Safety of Ly3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity Or Overweight: A Randomized Double-Blind Placebo-Controlled Trial (Triumph-1) $537,528 4 payments
  8. Study name not reported $494,536 102 payments
  9. A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Retatrutide Compared to Tirzepatide in Adults Who Have Obesity $468,311 4 payments
  10. A Phase III, Randomized, Controlled, Observer-Blind Study to Demonstra $462,535 79 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record